Delving into the Latest Updates on Allogeneic anti-CD33 CAR-T (Chinese People's Liberation Army General Hospital) with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms-

Target

CD33

Action

inhibitors

Mechanism

CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Chinese People's Liberation Army General Hospital

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.

Start Date01 Apr 2013

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

100 Clinical Results associated with Allogeneic anti-CD33 CAR-T (Chinese People's Liberation Army General Hospital)

Login to view more data

100 Translational Medicine associated with Allogeneic anti-CD33 CAR-T (Chinese People's Liberation Army General Hospital)

Login to view more data

100 Patents (Medical) associated with Allogeneic anti-CD33 CAR-T (Chinese People's Liberation Army General Hospital)

Login to view more data

100 Deals associated with Allogeneic anti-CD33 CAR-T (Chinese People's Liberation Army General Hospital)

Login to view more data